Free Cancer Report

Book Appointment with Dr Rajnish Vasant Nagarkar in Nashik

Dr Rajnish Vasant Nagarkar

Surgical Oncologist

19 Years Exp. Nashik

Breast Cancer

HCG Manavata Cancer Centre, Nashik

19 years of experience

MS , Basic Surgical Skills (BSS) Royal College of Surgeons , DNB

Nashik

About Dr Rajnish Vasant Nagarkar:

Dr Rajnish Nagarkar completed his graduation at a reputed college in Belgaum, Karnataka, after which he went on to pursue his MS at a prestigious institute in Mumbai, followed by BSS from Royal College of Surgeons, Edinburgh, and DNB from New Delhi. Dr Nagarkar has 17 years of experience in the field of Oncology and in this period, he has authored multiple books and journals. His papers and presentations have also been published in various publications, both nationally and internationally. He is also a recipient of various awards at the National level.

Education:

MBBS from Jawaharlal Nehru Medical College , Belgaum; 1996 MS from Tata Memorial Hospital, Mumbai; 2000 BSS from Royal College of Surgeons, Edinburgh; 2000 DNB from Ministry of Health, New Delhi; 2000 Membership of Royal college of Surgeons, Edinburgh (MRCSEd) Royal College of Surgeons, Edinburgh; 2000 Membership of National Academy of Medical Sciences (MNAMS) Ministry of Health, New Delhi; 2004 ICH-GCP Training in Various Investigators Meetings

Experience:

Managing Director & Chief Surgical Oncologist,HCG Manavata Cancer Centre,May 2007 Р Present

Memberships:

Maharashtra Oncology Group

Areas of interest:

Breast Cancer, Gastrointestinal (GI) Cancer.

Research publications:

Palwe, Vijay & Nagarkar, Rajnish. (2013). TACE plus sorafenib for the treatment of advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 31. e15178-e15178. https://doi.org/10.1200/jco.2013.31.15_suppl.e15178 Poveda, Andres & Oza, Amit & Fabbro, Michel & Redondo, AndrЋs & Bamias, Aristotle & Covens, Al & Romero, Ignacio & Bae, Duk-Soo & Censi, Andrea & Nagarkar, Rajnish & Richardson, Gary & Gallardo-Rinc—n, Dolores & Rasmussen, Erik & Rossi, John & Bass, Michael & Warner, Douglas & Monk, Bradley. (2014). Expression of angiopoietin (Ang) pathway markers and their relationship to progression-free survival (PFS) in TRINOVA-1.. Journal of Clinical Oncology. 32. 5542-5542. https://doi.org/10.1200/jco.2014.32.15_suppl.5542 Ahmad, Ateeq & Sheikh, Saifuddin & Mehta, Ajay & Nagarkar, Rajnish & Srinivasan, Krishnan & Majumdar, Anup & Mukherjee, Kalyan & Singh, Jitendra & Shrivastav, SP & Thungappa, Satheesh & Maksud, Tanveer & Pawar, Suraj & Sonawane, Satish & Kamat, Satish & Sharma, Manish & Rane, R. & Ahmad, Imran. (2014). Cremophor EL-free formulation of paclitaxel: A randomized, multicenter, safety, and efficacy study of nanosomal paclitaxel lipid suspension (NPLS) versus paclitaxel in women with metastatic breast cancer (MBC).. Journal of Clinical Oncology. 32. 573-573. https://doi.org/10.1200/jco.2014.32.15_suppl.573 Im, Young-Hyuck & Uslu, RџЌhan & Lee, Keun Seok & Nagarkar, Rajnish & Sohn, Joohyuk & Sevinc, Alper & Altundag, Kadri & Chang, Yuan-Ching & Abdel-Razeq, Hikmat & Im, Seock-Ah & Jeong, Joon & Park, Ho & Arpornwirat, Wichit & Bastick, Patricia & Le, Tuan & Arikan, Ozlem & Xue, Hong-Ling & Canatar, Aycin & Valenti, Roberta & Kim, Sung-Bae. (2015). Clinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.. Journal of Clinical Oncology. 33. e11579-e11579. https://doi.org/10.1200/jco.2015.33.15_suppl.e11579 Soulieres, Denis & Faivre, Sandrine & Mesia, R. & Remenar, Eva & Li, Shau-Hsuan & Karpenko, Andrey & Dechaphunkul, Arunee & Kiss, Laura & Lin, Jin-Ching & Nagarkar, Rajnish & Tamas, Laszlo & Kim, Sung-Bae & Erf‡n, Jozsef & Turri, Sabine & Dey, Debarshi & Chakravartty, Arunava & Aimone, Paola & Massacesi, Cristian & Licitra, Lisa. (2016). BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 34. 6008-6008. https://doi.org/10.1200/JCO.2016.34.15_suppl.6008 Viswabandya, Auro & Mukhopadhyay, Asis & Shah, Sandip & Nagarkar, Rajnish & Batra, Sonica & Lopez-Lazaro, Luis & Kankanwadi, Suresh & Srivastava, Alok. (2016). Comparison of Pharmacokinetics and Pharmacodynamics of Two Anti-CD20 Monoclonal Antibodies (Candidate Biosimilar DRL-Rituximab and Innovator Reference Product Rituximab (MabtheraЁ) in a Randomised, Multi-Centre, Double-Blind, Parallel Group Study of CHOP with Rituximab Chemotherapy in Patients with CD20-Positive Diffuse Large B-Cell Lymphoma. Blood. 128. 5391-5391. https://doi.org/10.1182/blood.V128.22.5391.5391 Shah, Sandip & Viswabandya, Auro & Mukhopadhyay, Asis & Nagarkar, Rajnish & Batra, Sonica & Lopez-Lazaro, Luis & Kankanwadi, Suresh & Srivastava, Alok. (2017). Comparative double-blind randomized trial of 2 rituximab products in patients with CD20+ diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 35. 7550-7550. https://doi.org/10.1200/JCO.2017.35.15_suppl.755 Viswabandya, Auro & Shah, Sandip & Mukhopadhyay, Asis & Nagarkar, Rajnish & Batra, Sonica & Lopez-Lazaro, Luis & Kankanwadi, Suresh & Srivastava, Alok. (2019). Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma. Journal of Global Oncology. 5. 1-13. https://doi.org/10.1200/JGO.19.00248

Specialisation

Breast Cancer, Gastrointestinal (GI) Cancer.